Clene vs Lexaria Bioscience
CLNN and LEXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLNN and LEXX compare
Lexaria Bioscience is the larger company, worth 2.5 times as much as Clene ($104M against $41.4M).
Clene grew revenue faster over the last twelve months (−31.1% versus −68.5% for Lexaria Bioscience).
Lexaria Bioscience keeps more of each dollar of sales as profit, with a net margin of −3986% compared with −20060% at Clene.
Lexaria Bioscience scores higher on the StockData Score (8 against 1 for Clene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLNN | LEXX |
|---|---|---|
| Size and price | ||
| Market cap | $41.4M | $104M |
| Share price | $3.22 | $4.18 |
| Change, 1 year | −62.2% | −73.7% |
| Change, 5 years | −96.6% | −94.8% |
| Beta (5Y) | 2.24 | 0.13 |
| Employees | 79 | 134 |
| StockData Score | ||
| Total score | 1 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 210× (better) | 534× |
| P/B | – | 21.9× |
| FCF yield | – | −7.2% |
| Growth | ||
| Revenue growth (TTM) | −31.1% (better) | −68.5% |
| Revenue growth, 5Y average | −0.59% | 17.5% (better) |
| Profitability | ||
| Gross margin | 70.1% | 100% (better) |
| Operating margin | −10432% | −3973% (better) |
| Net margin | −20060% | −3986% (better) |
| FCF margin | – | −3849% |
| Return on equity | – | −150% |
| Return on invested capital | – | −602% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −7.1× | – |
| Current ratio | 3.07 | 10.60 (better) |
| Altman Z-score | −21.93 | 117.82 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −6.3% |
| Shareholder yield | 0.00% (better) | −6.3% |
| Ownership | ||
| Held by institutions | 24.8% | – |
| Held by insiders | 45.9% | 3.0% |
| Insider net buying, 12 months | −$5.6M | – |
| Short interest, % of float | 6.0% | 0.90% |
Go deeper
- CLNN stock overview
- CLNN income statement
- CLNN valuation and score
- LEXX stock overview
- LEXX income statement
- LEXX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.